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Key questions
What is already known about this subject?
 ► There is evidence that women oncologists are un-
der-represented in leadership roles, but little infor-
mation is available about how they perceive their 
professional environment and the specific challeng-
es they encounter in career development, compared 
with their male colleagues.
What does this study add?
 ► This study provides insight into some of the chal-
lenges facing women oncologists in career develop-
ment and achieving leadership roles.
How might this impact on clinical practice?
 ► The results of this survey will inform future European 
Society for Medical Oncology initiatives aimed at 
supporting career development for oncologists, 
closing the gender gap in opportunities for leader-
ship roles and addressing other workplace challeng-
es. The findings identify areas on which regional and 
national organisations and specific institutions can 
focus their efforts in order to improve the workplace 
environment.
AbstrAct
Background Although women account for a growing 
proportion of the oncology workforce, there is evidence 
they are under-represented in leadership roles. To gain 
further insights into this issue and extend understanding 
of gender challenges, the European Society for Medical 
Oncology Women for Oncology (W4O) Committee 
undertook a survey of female and male oncologists in 
2016.
Design The 2016 W4O questionnaire included questions 
on (1) Demographics and professional environment, (2) 
Gender impact on career development, (3) Challenges 
for career progression and inappropriate behaviour 
experienced in the workplace, (4) Barriers for gender parity 
and (5) The gender gap. Between July and September 
2016, the online survey was available to male and female 
clinical and academic oncology healthcare professionals in 
the EU and internationally.
Results Responses were analysed from 462 oncologists, 
of whom 76.7 % were women. Of female respondents, 
45.5 % had a managerial or leadership role, compared 
with 65 % of male respondents (p<0.001). Men were more 
likely to have leadership roles, even in clinical teams with 
more women than men. Women respondents were more 
likely to consider their gender had a major impact on their 
career than men: 35.9 % vs 20.9 % (p<0.001). The biggest 
challenge to career progression for women was work 
and family balance (64.2%). Of female respondents, 14.4 
% believed there had been significant or major progress 
in closing the gender pay gap compared with 39.3 % of 
men (p<0.001). Of female participants, 37.7 % reported 
they had encountered unwanted sexual comments by a 
superior or colleague.
Conclusions New initiatives are needed to address 
under-representation of women oncologists in leadership 
roles, including greater and concrete promotion of work–
life balance, development and leadership training for 
women, and more support for flexible working. The fact 
that over a third of women in the survey had encountered 
unwanted sexual comments at work is of great concern 
and must be urgently addressed.
IntRoDuCtIon
Women make up a growing proportion of 
the medical workforce, and latest data from 
Organisation for Economic Co-operation 
and Development countries show a rise in 
female doctors from 39.1% in 2000 to 46.5% 
in 2015.1 With approximately half of medical 
students now women, this figure is likely 
to increase further in the coming years.2 
However, studies carried out among medical 
professionals consistently show that, although 
more women are becoming doctors, male 
doctors dominate leadership roles.3 4 There 
is also evidence of a gender pay gap, with 
recent UK surveys showing that full-time male 
doctors earn 56% more than full-time female 
doctors5 and male consultants earn 12% 
more than female consultants.6
An increasing proportion of oncologists 
are women.7–9 In a US audit of the oncology/
haematology workforce published in 2011, 
there were 3716 women, representing 28.4% 
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of the oncology/haematology workforce.7 By 2016, this 
had risen to 3859 women, representing 32% of the 
oncology/haematology workforce.8 A survey in 12 Euro-
pean countries showed that, between 2000 and 2012, 
the mean annual increase in medical oncologists was 
larger in female than male oncologists.9 For example, in 
Germany, there was an 11.9% increase in female oncolo-
gists compared with a 7.2% increase in male oncologists.9 
Female membership of the European Society for Medical 
Oncology (ESMO) is also increasing. In 2016, 40.5% of 
ESMO members were women—up from 24.9% in 2004 
and 35.2% in 2012—and, in 2017, 52.9% of young oncol-
ogist members of ESMO were women.10 In 2016, 37% of 
members of the American Society of Clinical Oncologists 
were women.11
In response to the rapid rise in female membership 
of ESMO, the Women for Oncology (W4O) initiative 
was established in 2013 to explore the challenges facing 
female oncologists and to promote equal access to career 
development opportunities. The W4O Committee has 
been tasked with generating and disseminating infor-
mation on the representation of women in the oncology 
workforce and to raise awareness and advocate for poli-
cies aimed at ensuring balanced gender representation in 
leadership positions in oncology.
In 2013, the W4O Committee carried out an explor-
atory survey among female oncologists which showed 
that, while the majority of medical oncologists working 
on clinical teams were women, most teams were 
managed by men.12 Indeed, nearly half of respon-
dents had no leadership or managerial role. The three 
greatest obstacles to career progression were finding 
a balance between work and family life, the fact that 
men were perceived as leaders while women were seen 
as team members and supporters, and cultural gender 
prejudice due to misconceptions about women’s family 
and domestic responsibilities.
To gain further insights into the current representa-
tion of women oncologists in leadership roles and to 
extend understanding of gender challenges to include 
perceptions of male oncologists, a further W4O survey 
with both female and male participants was performed 
in 2016. The aims included exploring female represen-
tation across different work environments (academia 
and clinics) and comparing male and female percep-
tions of the impact of gender on career development. 
The W4O Committee also wanted to explore the role 
of unconscious bias on gender parity in oncology and 
to better understand the perceived barriers to career 
development for women oncologists. The findings of 
the survey will be used to inform the activities of the 
ESMO W4O Committee to support the career develop-
ment of women in the oncology profession.
MetHoDs
The 2016 W4O survey was based on the 2013 question-
naire, which was updated and extended by the W4O 
Committee in order to address the additional goals of the 
new survey.
The questionnaire consisted of five sections that 
included questions related to (1) Demographics and 
professional environment, (2) Gender impact on career 
development, (3) Challenges for career progression and 
inappropriate behaviour experienced in the workplace, 
(4) Barriers for gender parity and (5) The gender gap.
In August 2016, the survey was made available online 
to male and female oncology professionals of all ages, 
working in a range of clinical and academic environments 
in the EU and internationally. It was promoted on the 
ESMO website, ESMO W4O and ESMO Facebook pages 
and through ESMO’s digital newsletters. The responses 
were anonymous.
Results are presented overall and by respondent’s 
gender and the corresponding associations are tested 
based on Fisher’s exact test or Mann-Whitney U test (at 
level of statistical significance α=5%). The Cochran-Man-
tel-Haenszel (CMH) test and Breslow-Day test of homo-
geneity were also used in cases where the joint effect 
of gender with other significant factors needed to be 
explored. Finally, multivariable ordinal logistic regres-
sion was used in order to investigate the effect of gender 
and a series of other respondents’ characteristics (profes-
sion, workplace, age, country, having children, covering 
a leadership role and experiencing unwanted sexual 
comments) on their beliefs. The backwards elimination 
method (with removal criterion p=10%) was deployed 
to come up with a final model with significant effects in 
each case. All statistical analysis was carried out in SAS 
V.4 (SAS Institute, Cary, North Carolina, USA) and R 
V.3.4.2 (R Foundation for Statistical Computing, Vienna, 
Austria).
Results
Description of analysis population
Responses were collected from 482 participants in total, 
but the analysis population consisted of 462 respond-
ents as 20 participants were excluded because they did 
not work directly in oncology healthcare. Of the 430 
respondents who stated their gender, 330 (76.7%) were 
women and 100 (23.3%) were men.
The majority of the respondents were medical oncol-
ogists (69.0%); 11.4% were trainees and 5.9% were 
radiation oncologists. Moreover, 39.8% of respondents 
worked primarily at a university hospital, 21.9% at a 
general hospital and 14.9% at a comprehensive cancer 
centre. Also, 76.7% of respondents were women, of 
whom 67.0% were aged under 45. Of the 23.3% of 
respondents who were men, 39.1% were under 45.
Respondents worked mainly in Europe (71.7%), with 
12.5% working in Asia, 8.6% in America, 4.4% in Africa 
and only 2.9% in Oceania. Of female respondents, 55.4% 
had children and 30.6% of them were primary carers of 
children while 82.6% of male respondents had children 
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A B
Figure 1 Box plots for distribution (%) of working team dedicated to different fields of work by respondent’s gender (A) and 
age (B).
and only 1.3% were primary carers (p<0.001) (online 
supplementary table 1).i
Professional environment
The distribution of respondents’ working time in specific 
fields of work is on average 60.4% clinical care, 19.6% 
research, 11.9% management and 8.1% teaching. Results 
by respondents’ gender indicate that the median working 
time dedicated to the fields of clinical care, teaching 
and management is significantly different for male and 
female respondents (60% for men vs 70% for women, 
p=0.039; 10% vs 5%, p=0.0014; and 10% vs 5%, p=0.023, 
respectively) (figure 1A). The distribution of working 
time also differs according to age for the three fields of 
work (figure 1B).
Among female respondents, 45.5% reported that they 
had a managerial or leadership role, compared with 65.0% 
of male respondents (p<0.001). Oncologists over 45 years 
old were more likely to lead their teams than oncolo-
gists under the age of 45 (79.9% vs 30.6%, p<0.001). Of 
note, the association of leadership role with gender is not 
significant when adjusted for age group (CMH, p=0.23; 
Breslow-Day, p=0.35): for respondents less than 45 years 
old, 28.6% of women and 41.7% of men had a leadership 
role (p=0.17), while for respondents of 45 years old and 
older, 79.6% of women and 80.4% of men had a leader-
ship role (p>0.99).
i For references to tables, see the ‘online supplementary table 1’ 
document submitted as supplementary material.
Overall, in most cases (59.4%), there were more women 
in a respondent’s work team than men, but a woman was 
responsible for the team in only 35.3% of cases. Men were 
more likely to lead, even in teams where there were fewer 
men than women (male leaders in 53.8% of teams with 
more women than men and in 82.3% of teams with more 
men).
Gender impact on career development
The impact of the respondent’s gender on his/her 
career was considered to have major or moderate signifi-
cance—35.9%/36.3% respectively of female responders, 
compared with 20.9%/19.8% respectively of male 
respondents (p<0.001) (figure S1).
Data on the impact of a respondent’s career on 
specific aspects of her/his daily life are presented in 
figure 2. Responses show that a woman’s career was 
significantly more likely to affect her friends, family and 
marriage, and time dedicated to childcare, parental 
leave and leisure activities than was the case for a man 
(all p<0.05).
Data on the career effects of a respondent’s personal 
choices for moving location, having children, reducing 
their working hours and taking extended parental leave 
are summarised in figure 3. Responses showed that the 
career impact of choices about having children and 
taking extended parental leave and reduced working 
hours, reported by women was significantly greater than 
that reported by men (all three p<0.001).
The statistically significant differences by responder’s 
gender remain significant (with the exception of impact 
on friends and leisure activities) even when taking into 
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Figure 2 Impact of career on daily life.
account related factors (multivariable ordinal logistic 
regressions presented in tables S2-S11).
Challenges for career progression and barriers for gender 
parity
The biggest challenges to career progression encoun-
tered by the female respondents were finding a balance 
between work and family (64.2%), the fact that men were 
perceived as natural leaders while women were perceived 
as team members and supporters (39.9%), and the diffi-
culty in spending time abroad for research (31.3%) and 
managing and organising family commitments (30.1%) 
(figure S2).
The main barriers that respondents felt prevent gender 
parity in the field of oncology are presented in figure 4. 
Overall, the greatest barrier was reported to be lack of 
work–life balance (52.8% of respondents), and this was 
the case for both female and male respondents (55.6% 
and 43.6%, respectively). More women (31.5%) than men 
(14.9%) believed that unconscious bias among managers 
disturbs gender parity (p=0.0015). Lack of qualified 
incoming talent constituted an important barrier for 
equality between genders for 13.8% of male respondents 
but for only 5.8% of female respondents (p=0.015).
Responses to a series of generalised statements about 
attitudes to working women, based on experiences 
previously reported by ESMO members, varied between 
female and male participants in the survey (figure 5 
provides average scores of agreement). For example, 
53.8% of women agreed or strongly agreed with the 
statement that successful men have a higher likeability 
factor than successful women, compared with 29.7% of 
men (p<0.001). In contrast, 14.3% of female respondents 
agreed or strongly agreed with the statement that women 
are less committed to their careers than men, compared 
with 22.4% of male respondents (p=0.0017). Similarly, 
22.3% of women in the survey agreed or strongly agreed 
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Figure 3 Impact of personal choices on career.
with the statement that a working mother is less moti-
vated to pursue a leadership career, compared with 44.1% 
of men who took part in the survey (p<0.001).
Additional findings are derived from the joint assess-
ment of related factors (tables S12-S18). The belief that 
women are less committed to their careers than men is 
significantly more prevalent for respondents working in 
general versus university hospitals.
Overall, 173/362 (47.8%) of participants who answered 
the question believed that there had been no or minor 
progress in closing the gender gap in the workplace since 
they started working, 32.0% believed there had been 
moderate progress and 20.2% significant or major prog-
ress. Among female respondents, only 14.4% believed 
there had been significant or major progress compared 
with 39.3% of male respondents (p<0.001).
The impression of unequal opportunities between men 
and women in the workplace was shared by 54.7% of all 
respondents (64.6% of female respondents vs 22.6% of 
male respondents; p<0.001), but 65.1% of respondents 
felt that their organisation practised ‘equal pay for equal 
work’ (58.3% of female respondents vs 87.1% of male 
respondents; p<0.001).
Of female participants, 37.7% reported that they had 
encountered unwanted sexual comments by a superior or 
colleague. These comments took the form of generalised 
sexist remarks and behaviours (69.0%), inappropriate 
sexual advances (19.8%), subtle bribery to engage in 
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Figure 4 Barriers to gender parity overall (N=405) and by respondent’s gender (311 women and 94 men).
sexual behaviours (8.6%), coercive advances (1.7%) and 
threats to engage in sexual behaviours (0.9%).
suggestions to address gender parity
To address gender parity, female and male respondents 
indicated that the three most important approaches 
were promotion of work–life balance (51.3% vs 47.3%, 
respectively, not significant), development and leader-
ship training for women (44.1% vs 29%, respectively, 
p=0.011), and the offer of support for flexible working 
(42.4% vs 35.5% respectively, not significant). Additional 
suggestions are shown in figure 6.
DIsCussIon
The results of the 2016 W4O workplace survey indicate 
that in 59.4% of clinical teams, the majority of oncologists 
are women but a higher proportion of leadership roles 
are filled by male oncologists rather than female oncolo-
gists (64.7% vs 35.3%).
In addition to the quantitative findings of the survey, 
individual responses from some participants offer further 
insights into the challenges facing women oncologists 
in achieving leadership roles. Some selected comments 
from female respondents are listed below: (1) ‘welcome 
to apply for a job but the male candidate is more likely to 
be viewed favourably’; (2) ‘men being selected for higher 
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Figure 5 Agreement with specific generalised statements.
positions despite equal or lower qualifications and skills’; 
(3) ‘men in leadership roles were more comfortable 
talking to other men’. Comments from male respondents 
include (1) ‘much of the fuss around gender equality is 
irrelevant in this current day and age’, (2) ‘main objec-
tive should be to support women so that they are good 
parents and pursue the career they want’, and (3) ‘we 
should focus more on ability and integrity and create 
more opportunities for those with abilities and integrity, 
be it female or male’.
The finding that women oncologists are less likely to 
play a leadership role than their male colleagues is not 
unusual. In a recent survey carried out by the Associ-
ation of American Medical Colleges, 51% of medical 
teaching staff at US medical schools were women, but 
only 20% were full professors and even fewer were heads 
of department.3 In another recent US study, female 
cardiologists were 37% less likely to become a full 
professor than their male colleagues, despite a doubling 
in the proportion of women entering the specialty over 
the last 20 years.4 In an observational study of leader-
ship roles in US obstetrics and gynaecology residency 
programmes accredited in 2012–2013, 20.2% of chairs 
were women, together with 36.1% of vice chairs, and 
29.6% of division directors.13 Similar gender disparity 
has been demonstrated in leadership roles in academic 
musculoskeletal radiology14 and neuroradiology.15 
Data from an ongoing prospective study of physicians 
7 years after graduation from medical schools in Swit-
zerland showed that women doctors, in particular those 
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Figure 6 Approaches to addressing gender parity.
with children, had less career success than their male 
contemporaries, were less advanced in their specialty 
qualification and less likely to have a mentor, tended to 
work in small hospitals or private practice, and aspired 
less often to senior hospital or academic positions.16
By surveying men as well as women, the 2016 W4O 
survey identified distinct perceptions of the impact of 
gender on career and of career on daily life. A higher 
proportion of women than men felt that their gender 
affected their career and that their career affected 
important aspects of their daily lives, such as their family 
and marriage, time devoted to childcare and parental 
leave. A higher proportion of female than male oncolo-
gists felt that choices about having children and taking 
extended parental leave affected their career, though 
lack of work–life balance was a major issue for both 
groups.
Women felt that there had been less progress in 
bridging the gender gap than men, and they were 
almost twice as likely to feel that women and men do not 
have equal opportunities in the workplace. The need to 
promote work–life balance, develop leadership training 
for women and offer flexible working was recognised by 
both male and female respondents.
The disparity between female and male perceptions 
of the effect of gender on career opportunities is illumi-
nating. The W4O survey suggests the need for greater 
awareness of the challenges faced by female oncologists 
across the clinical workforce and concerted efforts to 
address them at all levels.
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ESMO is taking steps to address these needs, with 
programmes to support members in career advance-
ment through preceptorship, mentor, sponsor and 
leadership programmes. In the 2017 Leaders Genera-
tion Programme, eight female and seven male oncol-
ogists learnt leadership skills through workshops and 
presentations by ESMO and external experts. Provi-
sion of childcare at the annual ESMO congress was 
introduced in 2017 so that lack of childcare is less of 
a barrier for participants wishing to engage in educa-
tional and networking opportunities. In parallel, ESMO 
will support national initiatives focusing on women’s 
careers, though legislative changes are needed in some 
countries. ESMO can also survey and promote gender 
balance, and develop initiatives that will lead to greater 
recognition of women in the competitive environ-
ment of academic research and education in medical 
oncology.
Although there was considerable agreement about the 
need for programmes to support female career devel-
opment in both the 2013 and 2016 W4O surveys, some 
respondents in the 2016 survey were wary of encouraging 
initiatives for women. ‘We need attitudes that promote 
generic equality of opportunity rather than a (paradoxi-
cally) sexist focus on gender,’ wrote one male participant. 
‘Gender equality should mean just that. I am as opposed 
to specialised activities and groups for women as I would 
be for men. Women are equal so why should we have 
these exclusive groups?’ asked a female respondent.
There are clearly strong opinions about how the 
gender gap in oncology careers should be bridged, and 
ongoing consultations for future strategies will be the 
key.
In contrast, there can be no compromise concerning 
the issue of sexual harassment in the workplace. The 
fact that the 2016 W4O survey showed that a significant 
proportion of women had encountered unwanted sexual 
comments and behaviour by superiors or colleagues is 
of great concern, particularly in the current climate 
of zero tolerance of inappropriate sexual conduct. In 
our survey, 37.7% of respondents had encountered 
unwanted sexual comments by a superior or colleague, 
compared with rates of sexual harassment ranging from 
30% to 52% in previous studies of women in academic 
medicine.17
survey limitations
There may have been selection bias in the survey, 
depending on those who elected to take part. Of note, 
the majority of the female respondents were aged under 
45 (67%), while among male respondents only 39.1% 
were under 45.
As the denominator is not known, we cannot say what 
proportion of the total oncologist population world-
wide, or even in Europe, is represented in our survey. 
The primary work place of the majority of respondents 
(76.7%) was in Europe, so our sample may not be repre-
sentative of the oncologist profession worldwide.
Further surveys are planned, with the aim of obtaining 
wider representation across oncology healthcare profes-
sionals (eg, nurses, pharmacists), enlarging the geograph-
ical coverage of potential diversity and exploring 
variation in career opportunity and childcare availability 
in different countries.
In addition, data on ESMO membership might vary by 
a few percentage points at specific time points because 
of the evolving nature of the ESMO database. Neverthe-
less, this variation does not impact on the trends brought 
forth in this article.
ConClusIons
Although there are generally more women oncologists in 
clinical teams than men, women oncologists are less likely 
to have leadership roles and they feel that their gender 
is adversely affecting their career. Women feel that less 
progress has been made in closing the gender gap than 
men and they feel affected by unequal opportunities in 
the workplace. The fact that over a third of women in the 
survey had encountered unwanted sexual comments at 
work is of great concern and must be urgently addressed. 
New initiatives are needed to address under representa-
tion of women oncologists in leadership roles, including 
greater promotion of work–life balance, development 
and leadership training for women, and more support 
for flexible working.
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